Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Thoracic lung cancer treatment often induces lung toxicity as an adverse effect of
concomitant therapy (CCRT) using chemo or target therapy drugs in addition to radiation
therapy, in non-small cell lung cancer (NSCLC) patients with advanced disease. The presence
of Pneumonitis is the most severe acute lung injury derived from this intervention.
Pneumonitis might evolve to respiratory failure and even death, with a high incidence in the
investigator's population (50%) as reported in different studies. Its prevention with
different immunomodulatory targets has not succeeded. The use of inhaled steroids is used in
various pathologies such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) to reduce
the airway inflammatory response. The advantage of using inhaled corticosteroids as opposed
to orally administered drugs bases in the low incidence of systemic side effects and the fact
that its use does not require tapering. Currently, the effectiveness of using prophylactic
inhaled steroids for reducing the incidence of CCRT-induced pneumonitis and its impact
regarding the quality of life has not been demonstrated in a clinical trial.